A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications

Nature Medicine

Volumn 16, Issue 6, 2010, Pages 671-677

  Sheng, Zhi ^a   Li, Li ^a   Zhu, Lihua J ^a   Smith, Thomas W ^a   Demers, Andrea ^a   Ross, Alonzo H ^a   Moser, Richard P ^a   Green, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ACTIVATING TRANSCRIPTION FACTOR 5; CAMP RESPONSE ELEMENT BINDING PROTEIN 3 LIKE 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1; RAS PROTEIN; SORAFENIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVATION; GENETIC SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION REGULATION;

ACTIVATING TRANSCRIPTION FACTORS; ANIMALS; APOPTOSIS; BENZENESULFONATES; BRAIN NEOPLASMS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 77953230937     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2158     Document Type: Article

References (51)

1. Hanahan, D. & Weinberg, R.A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Luo, J., Solimini, N.L. & Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
3. Persengiev, S.P. & Green, M.R. The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis 8, 225-228 (2003).
4. Greene, L.A., Lee, H.Y. & Angelastro, J.M. The transcription factor ATF5: role in neurodevelopment and neural tumors. J. Neurochem. 108, 11-22 (2009).
5. Monaco, S.E., Angelastro, J.M., Szabolcs, M. & Greene, L.A. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines. Int. J. Cancer 120, 1883-1890 (2007).
6. Angelastro, J.M. et al. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5. Oncogene 25, 907-916 (2006).
7. Persengiev, S.P., Devireddy, L.R. & Green, M.R. Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors. Genes Dev. 16, 1806-1814 (2002).
8. Collier, R.J. Diphtheria toxin: mode of action and structure. Bacteriol. Rev. 39, 54-85 (1975).
9. Silva, J.M. et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat. Genet. 37, 1281-1288 (2005).
10. Sato, T. & Gotoh, N. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opin. Ther. Targets 13, 689-700 (2009).
11. Da Fonseca, C.O. et al. Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg. Neurol. 65 Suppl. 1, S1:2-1:8; discussion S1:8-1:9 (2006).
12. Kumar, R., Gururaj, A.E. & Barnes, C.J. p21-activated kinases in cancer. Nat. Rev. Cancer 6, 459-471 (2006).
13. Kondo, S. et al. BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer. Mol. Cell. Biol. 27, 1716-1729 (2007).
14. Lonze, B.E. & Ginty, D.D. Function and regulation of CREB family transcription factors in the nervous system. Neuron 35, 605-623 (2002).
15. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904 (1998).
16. Discafani, C.M. et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]- 6-quinazolinyl]-2-butynamide (CL-387,785). Biochem. Pharmacol. 57, 917-925 (1999).
17. Hara, M. et al. Identifcation of Ras farnesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90, 2281-2285 (1993).
18. Wilhelm, S. & Chien, D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 8, 2255-2257 (2002).
19. Favata, M.F. et al. Identifcation of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623-18632 (1998).
20. Ohori, M. et al. Identifcation of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 336, 357-363 (2005).
21. Vlahos, C.J., Matter, W.F., Hui, K.Y. & Brown, R.F. A specifc inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem. 269, 5241-5248 (1994).
22. Cuenda, A. et al. SB 203580 is a specifc inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229-233 (1995).
23. Bonny, C., Oberson, A., Negri, S., Sauser, C. & Schorderet, D.F. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50, 77-82 (2001).
24. Yu, C. et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861-6869 (2005).
25. Rhodes, D.R. et al. Oncomine 3.0: genes, pathways and networks in a collection of 18,000 cancer gene expression profles. Neoplasia 9, 166-180 (2007).
26. Sun, L. et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9, 287-300 (2006).
27. Fischer, U. et al. A different view on DNA amplifcations indicates frequent, highly complex, and stable amplicons on 12q13-21 in glioma. Mol. Cancer Res. 6, 576-584 (2008).
28. Aoki, H. et al. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clin. Cancer Res. 13, 6603-6609 (2007).
29. Pelloski, C.E. et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin. Cancer Res. 12, 3935-3941 (2006).
30. Parsons, D.W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
31. Rahmani, M. et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol. 27, 5499-5513 (2007).
32. Rahmani, M., Davis, E.M., Bauer, C., Dent, P. & Grant, S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227 (2005).
33. Alcantara Llaguno, S. et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15, 45-56 (2009).
34. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
35. Li, L. et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro-oncol. 11, 9-21 (2009).
36. Villano, J.L., Seery, T.E. & Bressler, L.R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother. Pharmacol. 64, 647-655 (2009).
37. Weiss, W.A., Taylor, S.S. & Shokat, K.M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3, 739-744 (2007).
38. Sparidans, R.W. et al. Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identifcation of the glucuronide metabolite. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 269-276 (2009).
39. Lagas, J.S. et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol. Cancer Ther. 9, 319-326 (2010).
40. Hu, S. et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin. Cancer Res. 15, 6062-6069 (2009).
41. Awada, A. et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92, 1855-1861 (2005).
42. Strumberg, D. et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23, 965-972 (2005).
43. Clark, J.W., Eder, J.P., Ryan, D., Lathia, C. & Lenz, H.J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11, 5472-5480 (2005).
44. Richly, H. et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann. Oncol. 17, 866-873 (2006).
45. McCubrey, J.A. et al. Emerging Raf inhibitors. Expert Opin. Emerg. Drugs 14, 633-648 (2009).
46. Jung, S. et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17, 211-220 (2002).
47. Gazin, C., Wajapeyee, N., Gobeil, S., Virbasius, C.M. & Green, M.R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449, 1073-1077 (2007).
48. Sheng, Z., Wang, S.Z. & Green, M.R. Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3R. EMBO J. 28, 866-876 (2009).
49. Sen, A., Kallos, M.S. & Behie, L.A. New tissue dissociation protocol for scaled-up production of neural stem cells in suspension bioreactors. Tissue Eng. 10, 904-913 (2004).
50. Ihaka, R. & Gentleman, R. A language for data analysis and graphics. J. Comput. Graph. Statist. 5, 299-314 (1996).
51. Ruxton, G.D. The unequal variance t-test is an underused alternative to Student's t-test and the Mann-Whitney U test. Behav. Ecol. 17, 688-690 (2006).